- AU$18.50m
- AU$14.04m
- AU$2.85m
- 21
- 12
- 45
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.69 | ||
| Price to Tang. Book | 3.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -102.1% | ||
| Return on Equity | -68.99% | ||
| Operating Margin | -302.26% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.84 | 0.77 | 1.34 | 3.33 | 2.85 | n/a | n/a | 40.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 8th, 2006
- Public Since
- July 13th, 2007
- No. of Shareholders
- 3,813
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 2,055,750,236
- Address
- C:/ Leydin Freyer, SOUTH MELBOURNE, 3205
- Web
- https://patrys.com/
- Phone
- +61 396703273
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for PAB
Similar to PAB
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Patrys share price?
As of Today at 19:16 UTC, shares in Patrys are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Patrys share price performed this year?
Shares in Patrys last closed at AU$0.01 and the price had moved by -43.75% over the past 365 days. In terms of relative price strength the Patrys share price has underperformed the ASX All Ordinaries Index by -46.2% over the past year.
What are the analyst and broker recommendations for Patrys?
There is no consensus recommendation for this security.
What is the Patrys dividend yield?
Patrys does not currently pay a dividend.
Does Patrys pay a dividend?
Patrys does not currently pay a dividend.
When does Patrys next pay dividends?
Patrys does not currently pay a dividend.
How do I buy Patrys shares?
To buy shares in Patrys you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Patrys?
As of the previous close price of AU$0.01, shares in Patrys had a market capitalisation of AU$18.50m.
Where are Patrys shares listed?
Here are the trading details for Patrys:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PAB
What kind of share is Patrys?
Based on an overall assessment of its quality, value and momentum Patrys is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Patrys share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Patrys share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Patrys. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +0.12%.
As of the last closing price of AU$0.01, shares in Patrys were trading +1.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Patrys PE Ratio?
The Patrys PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Patrys?
Patrys' management team is headed by:
- John Read - NEC
- James Campbell - CEO
- Michael Stork - NVC
- Stefan Ross - SEC
- Pamela Klein - NED
- Susan Jones - NID